On April 8, Daol Investment & Securities stated that Interojo is expected to see an increase in sales through the sequential approval of silicone hydrogel lenses by regulatory authorities in major countries, as well as the launch of direct-to-consumer (D2C) sales targeting domestic consumers.


"Interojo Anticipates Sequential Overseas Approvals for Silicone Hydrogel Lenses" View original image

Jonghyun Park, a researcher at Daol Investment & Securities, said, "From 2026, domestic net sales are expected to show an upward trend, and the company plans to establish five to six flagship stores during 2026 to support D2C sales." He added, "By diversifying the sales channels from the traditional agency and optical shop model, domestic sales growth is anticipated."


Park further explained, "Internationally, approval from the U.S. Food and Drug Administration (FDA) for silicone hydrogel clear frequent replacement lenses (FRP) is expected in May 2026. In addition, three more products are anticipated to receive approval within 2026, and approvals for silicone lenses in Japan and China are also projected in 2027."



Park noted, "The company, which has received an unqualified audit opinion for two consecutive years, is expected to expand its sales this year through overseas regulatory approvals for silicone hydrogel lenses and the launch of D2C sales in Korea." He forecasted, "This year, we expect sales of 141 billion won and operating profit of 31.9 billion won."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing